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Key PointsLong‐term outcomes in patients with status epilepticus are predicted by underlying etiologyLong‐term mortality after status epilepticus is seen in up to 20% of children and 55% of adultsStatus epilepticus is associated with increased rates of status epilepticus recurrence, subsequent epilepsy, and worsening of previous epilepsyFurther studies using standardized tools are in progress to assess quality of life and functional and cognitive outcomePromising research suggests that functional outcome may improve over time

1. INTRODUCTION {#epi14515-sec-0002}
===============

Status epilepticus (SE), especially refractory SE (RSE), is a life‐threatening condition often requiring intensive care.[1](#epi14515-bib-0001){ref-type="ref"}, [2](#epi14515-bib-0002){ref-type="ref"}, [3](#epi14515-bib-0003){ref-type="ref"}, [4](#epi14515-bib-0004){ref-type="ref"} Long‐term sequelae may include neurological, cognitive, and behavioral impairments and decline in quality of life (QoL),[4](#epi14515-bib-0004){ref-type="ref"}, [5](#epi14515-bib-0005){ref-type="ref"} and impose heavy burdens on the patient, the caregivers, and the healthcare system. Outcomes are influenced by type of epilepsy, type of SE, etiology, SE duration, and patient\'s age.[4](#epi14515-bib-0004){ref-type="ref"} This review aims to provide an overview of long‐term outcomes in patients with SE.

2. LITERATURE SEARCH {#epi14515-sec-0003}
====================

We performed a search of the medical literature using the following strategy in PubMed: ("status epilepticus") AND ("long‐term outcome" OR "long‐term mortality" OR "long‐term morbidity" OR "quality of life"), gathering 570 articles. Our search was restricted to full‐length clinical studies in humans written in the English language until December 1, 2017. We excluded studies focusing on the neonatal period (1‐28 days of postnatal age at the beginning of SE) and studies evaluating solely short‐term outcome or very specific subgroups of patients. In addition, we added relevant articles from the reference lists of articles from the primary search. We included the results of 37 relevant studies, 16 on children (Table [1](#epi14515-tbl-0001){ref-type="table"}), 14 on adults and seven on a mixed population of adults and children (Table [2](#epi14515-tbl-0002){ref-type="table"}), reporting long‐term outcomes after SE (ie, after hospital discharge or \>1 month from SE onset), and reviewed studies for predictors of outcome (Figure [1](#epi14515-fig-0001){ref-type="fig"}).

###### 

Pediatric studies on long‐term outcome after SE

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors, study design                                                                 Year   Population                                                                                                           Follow‐up testing/scores                                Mortality rate                    Outcome: epilepsy                                                                         Outcome: cognitive abilities                                                                                      Outcome: QoL                                                                                                        Outcome: functional outcome/other                                    Predictors
  ------------------------------------------------------------------------------------- ------ -------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------- --------------------------------- ----------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Chevrie & Aicardi,[38](#epi14515-bib-0038){ref-type="ref"} prospective                1978   Children 28 d‐1 y, n = 313, SE: n = 40                                                                               \>1 y, median 3 y, no formal testing                    22%, patients with SE             N/A                                                                                       Severe intellectual disability in SE: 60%                                                                         N/A                                                                                                                 Neurological sequelae in SE: 43%                                     Cognitive abilities; poor outcome: symptomatic cases, age \< 6 mo; good outcome: positive family history; functional outcome: pre‐ or perinatal abnormality

  Maytal et al,[26](#epi14515-bib-0026){ref-type="ref"} retrospective and prospective   1989   Children in SE, n = 193                                                                                              13.2 mo, no formal testing                              3.6%, at 3 mo                     New epilepsy: 30%                                                                         N/A                                                                                                               N/A                                                                                                                 Neurologic deficits, motor or cognitive: 9.1%                        Functional outcome: duration of SE (in the acute symptomatic group), etiology (acute or progressive insults)

  Shinnar et al,[35](#epi14515-bib-0035){ref-type="ref"} prospective                    1992   Children with first SE, n = 95                                                                                       29 mo, no formal testing                                3 died within 10 d                Recurrence: 17%                                                                           N/A                                                                                                               N/A                                                                                                                 No deterioration in neurological function                            Recurrence: underlying neurological abnormality, etiology (remote symptomatic and progressive causes)

  Eriksson & Koivikko,[27](#epi14515-bib-0027){ref-type="ref"} retrospective            1997   Children in SE, n = 65                                                                                               3.6 y                                                   0%                                New epilepsy: 23%                                                                         N/A                                                                                                               N/A                                                                                                                 Neurological sequelae: 15%                                           Functional outcome: SE duration \> 2 h

  Barnard & Wirrell,[28](#epi14515-bib-0028){ref-type="ref"} retrospective              1999   Children in SE, n = 47                                                                                               53 mo, developmental quotient                           15.4%                             New epilepsy: 36%; recurrent seizures: 85%; refractory epilepsy: 25%; recurrent SE: 50%   Neurodevelopmental deterioration: 34% (26%: severe)                                                               School: normal (6%), resource assistance (14%), teaching aides (37%), special class (43%); behavior problems: 41%   Neurological sequelae: 79% (mild: 21%, moderate: 28%, severe: 34%)   Functional outcome: etiology (nonfebrile‐nonidiopathic), perinatal difficulties, developmental delay, abnormal neurologic examination; abnormal neuroimaging; developmental deterioration: etiology, neuroimaging, young age; epilepsy: etiology

  Kim et al,[24](#epi14515-bib-0024){ref-type="ref"} case series                        2001   Children in RSE treated with pentobarbital, n = 23                                                                   4 y                                                     43.5%, in hospital                N/A                                                                                       N/A                                                                                                               N/A                                                                                                                 Neurological sequelae: 61.5%                                         Mortality: failure of seizure control after PB coma, acute symptomatic etiology; functional outcome: treatment delayed

  Tabarki et al,[36](#epi14515-bib-0036){ref-type="ref"} retrospective                  2001   Children in SE, n = 139                                                                                              3.5 y, no formal testing                                15.8%, within 2 mo                Epilepsy without cognitive deterioration: 5%                                              Moderate intellectual disability: 11.5%; severe: 19.5%;\                                                          N/A                                                                                                                 N/A                                                                  Functional and cognitive outcome: etiology (remote symptomatic and progressive encephalopathy \> acute symptomatic \> febrile and idiopathic); age \< 1 y
                                                                                                                                                                                                                                                                                                                                                                                                        remission: 48%                                                                                                                                                                                                                                                                                             

  Sillanpää & Shinnar,[34](#epi14515-bib-0034){ref-type="ref"} prospective              2002   Children with childhood onset epilepsy, n = 150, 27% with SE, n = 41                                                 30 y                                                    16%                               Recurrence of SE: 56%; remission: 55% (compared to 80% in children without SE)            N/A                                                                                                               Comparing SE or not: similar social and educational outcome                                                         N/A                                                                  Mortality and social outcome: occurrence of SE did not alter mortality rate and social and educational outcome; remission rates: slightly affected by SE

  Metsäranta et al,[6](#epi14515-bib-0006){ref-type="ref"} retrospective                2004   Children in SE, n = 186                                                                                              2 y and 1 mo, no formal testing                         0%                                New onset epilepsy: 22%                                                                   N/A                                                                                                               N/A                                                                                                                 Permanent neurological sequelae: 2.2%, temporary sequelae: 3.2%      Minor neurological sequelae: duration of seizure; major neurological sequelae: acute symptomatic cause; temporary sequelae: febrile SE

  Maegaki et al,[17](#epi14515-bib-0017){ref-type="ref"} retrospective                  2005   Children in SE, n = 234                                                                                              64 mo, no formal testing                                4%                                N/A                                                                                       N/A                                                                                                               N/A                                                                                                                 Neurological sequelae: 15%                                           Mortality/functional outcome: etiology (acute neurological insult and progressive neurological disease), seizure duration (\>2 h), asthmatic attack

  Hussain et al,[29](#epi14515-bib-0029){ref-type="ref"} retrospective                  2007   Children in SE, n = 137                                                                                              1.5 y, no formal testing                                0%                                New epilepsy: 5%; recurrence of SE: 10%                                                   N/A                                                                                                               N/A                                                                                                                 Neurological sequelae among previously normal children: 1.4%         New epilepsy: remote symptomatic group, no correlation with duration of SE

  Wagenman et al,[45](#epi14515-bib-0045){ref-type="ref"} prospective                   2014   Children with acute neurologic disorders neurodevelopmentally normal before PICU admission with ES or ESE, n = 137   2.7 y, GOS‐E Peds and PedsQoL                           0%                                Subsequent seizures: 35%                                                                  N/A                                                                                                               PedsQoL: median = 94 for SE and 62 for ESE                                                                          Unfavorable outcome GOS‐E Peds: 35%                                  Functional impairment: ESE; subsequent seizures: ESE

  Pujar et al,[53](#epi14515-bib-0053){ref-type="ref"} prospective                      2011   Children with convulsive SE, n = 206                                                                                 8 y                                                     3% within 1 mo, 11% within 8 y    N/A                                                                                       N/A                                                                                                               N/A                                                                                                                 N/A                                                                  Mortality: preexisting clinically significant neurological impairments;\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   better outcome: prolonged febrile convulsions\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   and idiopathic convulsive SE

  Camfield & Camfield,[33](#epi14515-bib-0033){ref-type="ref"} retrospective            2012   Children with focal epilepsy and normal intelligence (acute symptomatic causes not included), n = 188 (20% SE)       Mean 27 y, wide variety of testing                      0%                                Seizure‐free: 61.5% with SE vs 66.4% without SE; intractability: 15% vs 11.4%             Learning disorders: 28 with SE vs 33% without SE                                                                  N/A                                                                                                                 N/A                                                                  Cognitive outcome and epilepsy: no difference between the SE and non‐SE groups

  Martinos et al,[37](#epi14515-bib-0037){ref-type="ref"} prospective                   2013   Children from 1 to 42 mo, in SE (febrile or not), n = 54                                                             At 6 wk and 1 y, Bayley Scales of Infant Development\   1 patient died during follow‐up   N/A                                                                                       Cognitive composite: FSE, 93; non‐FSE, 74; control, 107; language composite: FSE, 91; non‐FSE, 75; control, 114   N/A                                                                                                                 Motor composite: FSE, 96; non‐FSE, 77; control, 103                  Developmental outcome: nonfebrile SE \< FSE \< controls
                                                                                                                                                                                                                    III                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Ferro et al,[5](#epi14515-bib-0005){ref-type="ref"} retrospective                     2014   Children with newly diagnosed epilepsy, n = 374 (SE: 6.1%)                                                           24 mo, Quality of Life in Childhood Epilepsy Score      0%                                N/A                                                                                       No cognitive deterioration                                                                                        Poorer QoL in children with SE                                                                                      N/A                                                                  N/A
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ES, electrographic seizure; ESE, electrographic SE; FSE, febrile status epilepticus; GOS‐E, Glasgow Outcome Scale--extended; GOS‐E Peds, pediatric Glasgow Outcome Scale--extended; N/A, nonapplicable; PB, pentobarbital; PedsQoL, Pediatric Quality of Life Inventory; PICU, pediatric intensive care unit; QoL, quality of life; RSE, refractory SE; SE, status epilepticus.
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###### 

Adult or adult and pediatric studies on long‐term outcome after SE

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors, study design                                                                    Year   Population                                                       Follow‐up testing/scores                           Mortality rate                                  Outcome: epilepsy                                                     Outcome: functional outcome/other                                          Predictors
  ---------------------------------------------------------------------------------------- ------ ---------------------------------------------------------------- -------------------------------------------------- ----------------------------------------------- --------------------------------------------------------------------- -------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------
  DeLorenzo et al,[13](#epi14515-bib-0013){ref-type="ref"} retrospective and prospective   1992   Adults and children in SE, n = 546                               7 y                                                Children: 2.3%,\                                N/A                                                                   N/A                                                                        Mortality: etiology (tumor, hematological disease, anoxia, metabolic and congenital malformation), age, SE duration (for short‐term mortality)
                                                                                                                                                                                                                      adults: 25%                                                                                                                                                                                      

  DeLorenzo et al,[8](#epi14515-bib-0008){ref-type="ref"} prospective                      1996   Adults and children with a first SE, n = 166                     2 y                                                Children: 3%,\                                  Recurrence of SE at 2 y: 13.3%                                        N/A                                                                        Mortality: SE duration, etiology (hypoxia); recurrence: age
                                                                                                                                                                                                                      adults: 26% (at 30 d)                                                                                                                                                                            

  Hesdorffer et al,[30](#epi14515-bib-0030){ref-type="ref"} retrospective                  1998   Adults and children; acute symptomatic SE vs seizures, n = 416   10 y                                               N/A                                             New unprovoked epilepsy: 41% in the SE group vs 13% in non‐SE group   N/A                                                                        Epilepsy: SE, etiology (anoxia, structural or metabolic cause)

  Logroscino et al,[55](#epi14515-bib-0055){ref-type="ref"} retrospective                  2002   Adults and children, n = 145                                     30 d to 12 y                                       43% (at 10 y)                                   N/A                                                                   N/A                                                                        Mortality: SE duration, etiology (acute symptomatic cause), myoclonic SE

  Holtkamp et al,[14](#epi14515-bib-0014){ref-type="ref"} retrospective                    2005   Adults and children (11‐94 y) in SE, n = 79                      Unclear, telephone calls (only for "de novo" SE)   RSE: 16.7%; SE, 8.6% (in hospital)              New symptomatic epilepsy: 22% in SE and 87.5% in RSE                  N/A                                                                        Epilepsy: RSE predicted by encephalitis

  Adachi et al,[10](#epi14515-bib-0010){ref-type="ref"} prospective                        2005   Adults in SE (n = 15) or with epilepsy (n = 40)                  3.2 y, IQ and Weschler Adult Intelligence Scale    0%                                              N/A                                                                   No cognitive decline                                                       Cognitive abilities: no influence of age, CPSE, GCSE, SE duration, etiology (AED withdrawal or unknown)

  Hesdorffer et al,[9](#epi14515-bib-0009){ref-type="ref"} retrospective                   2007   Adults and children with a first afebrile SE, n = 183            10 y                                               Unclear                                         Recurrence: 37% (30% among 30‐d survivors)                            N/A                                                                        Recurrence: female gender, failure to respond the first drug administrated, progressive symptomatic cause

  Logroscino et al,[11](#epi14515-bib-0011){ref-type="ref"} retrospective                  2008   Adults, unprovoked epilepsy (n = 291) or SE (n = 16)             10 y                                               9% without SE vs 31% with SE                    N/A                                                                   N/A                                                                        Mortality: age, development of subsequent epilepsy

  Cooper et al,[15](#epi14515-bib-0015){ref-type="ref"} retrospective                      2009   Adults with PRSE, n = 14                                         Median of 313 d, mRS                               43% (in hospital), 57% (last follow‐up)         N/A                                                                   No change for 2 patients and improvement for 4 patients (mRS change: −1)   None

  Legriel et al,[20](#epi14515-bib-0020){ref-type="ref"} prospective                       2010   Adults in SE, n = 248                                            90 d, GOS                                          18.8% (4 patients died during the follow‐up)    New epilepsy or worsening of previous epilepsy: 33.5%                 Neurological sequelae (GOS = 2‐4): 38.8%                                   Functional impairment (GOS \< 5): older age, focal neurological signs, RSE, cerebral insults, SE duration

  Ristić et al,[12](#epi14515-bib-0012){ref-type="ref"} prospective                        2010   Adults in SE, n = 750                                            12 y                                               16% (short term), 22% (long term)               N/A                                                                   N/A                                                                        Mortality: etiology (progressive and acute symptomatic), age, epilepsy, initial SE

  Kilbride et al,[21](#epi14515-bib-0021){ref-type="ref"} retrospective                    2013   Adults in PRSE, n = 63                                           At least 6 mo, mRS                                 34% (in hospital) and 5 died during follow‐up   Seizure‐free: 20%; no recurrence                                      Good outcome: mRS ≤ 3: 22%; mRS = 1: 10%                                   Functional outcome: normal neuroimaging and a reactive EEG at SE onset

  Li et al,[23](#epi14515-bib-0023){ref-type="ref"} case series                            2014   Adults in SRSE, n = 13                                           Median 17 mo, GOS                                  36.3% (at 3 mo); 15.4% (in hospital)            50%                                                                   At 3 mo: mean GOS = 4.1;\                                                  Functional outcome at 3 mo:\
                                                                                                                                                                                                                                                                                                                                            at 17 mo: mean GOS = 4.6                                                   etiology (encephalitis), longer period of anesthesia

  Jayalakshmi et al,[16](#epi14515-bib-0016){ref-type="ref"} retrospective                 2014   Adults and children, n = 177                                     6 mo, GOS                                          19%                                             N/A                                                                   Good outcome (GOS = 4‐5): SRSE, 33%; non‐RSE, 79%; RSE, 57%                Functional outcome: SRSE predicted by presumed encephalitis

  Lai et al,[54](#epi14515-bib-0054){ref-type="ref"} retrospective                         2015   Adults in PRSE,\                                                 1 y, telephone calls (mRS)                         52%                                             N/A                                                                   Poor outcome (mRS = 4‐6): 67%                                              Functional outcome (mRS = 4‐6): vasopressor use
                                                                                                  n = 78                                                                                                                                                                                                                                                                                                               

  Madzar et al,[44](#epi14515-bib-0044){ref-type="ref"} retrospective                      2016   Adults in RSE, n = 65                                            12 wk, mRS                                         18% (in hospital)                               N/A                                                                   mRS \> 2: 61%                                                              Poor functional outcome: STESS ≥ 3, longer RSE duration (10 d), sepsis

  Legriel et al,[43](#epi14515-bib-0043){ref-type="ref"} retrospective                     2016   Adults in SE, n = 268                                            90 d, GOS                                          13.8% (in hospital); 14.1% (at 90 d)            N/A                                                                   Good outcome (GOS = 5): 46%                                                No association with hypothermia

  Kortland et al,[18](#epi14515-bib-0018){ref-type="ref"} retrospective                    2017   Adults in SE, n = 81 (RSE: n = 33)                               3 mo, mRS, QOLIE‐31, NDDI‐E                        0%                                              Hospitalization due to epilepsy: 22.2%                                mRS = 0‐3: 60.8% (RSE: 70%);\                                              N/A
                                                                                                                                                                                                                                                                                                                                            major depression: 32.8%\                                                   
                                                                                                                                                                                                                                                                                                                                            (QOLIE‐31: SE: 43.5%, RSE: 42.5%)                                          

  Atmaca et al,[19](#epi14515-bib-0019){ref-type="ref"} prospective                        2017   Adults in SE, n = 59 (RSE: n = 15)                               13.6 ± 4.6 mo                                      31%                                             N/A                                                                   Poor outcome (death or neurological sequelae): 46%                         Mortality and functional outcome:\
                                                                                                                                                                                                                                                                                                                                                                                                                       potentially fatal etiology,\
                                                                                                                                                                                                                                                                                                                                                                                                                       EMSE score \> STESS, mSTESS

  Kantanen et al,[58](#epi14515-bib-0058){ref-type="ref"} retrospective                    2017   Adults in RSE, n = 395                                           1 y                                                25%                                             N/A                                                                   N/A                                                                        Mortality: older age, SOFA score, dependence of activities in daily living, SRSE

  Kantanen et al,[59](#epi14515-bib-0059){ref-type="ref"} retrospective                    2017   Adults in RSE, n = 75 (SRSE: 21%)                                1 y, mRS                                           23 (at 1 y); 7% (in hospital)                   N/A                                                                   Neurological deficits: 29%;\                                               Mortality: older age
                                                                                                                                                                                                                                                                                                                                            mRS = 4‐6: 52%                                                             
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AED, antiepileptic drug; CPSE, complex partial SE; EEG, electroencephalogram; EMSE, epidemiology‐based mortality in SE; GCSE, generalized convulsive SE; GOS, Glasgow Outcome Scale; IQ, intelligence quotient; mRS, modified Rankin Score; mSTESS, modified STESS; N/A, nonapplicable; NDDI‐E, Neurological Disorders Depression Inventory for Epilepsy; PRSE, prolonged refractory SE; QOLIE, Quality of Life in Epilepsy; RSE, refractory SE; SE, status epilepticus; SOFA, Sequential Organ Failure Assessment; SRSE, super‐refractory SE; STESS, Status Epilepticus Severity Score.
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3. DEFINITIONS {#epi14515-sec-0004}
==============

In 15 pediatric studies, SE was defined as any seizure lasting \>30 minutes or recurrent seizures lasting a total of \>30 minutes without the subject fully regaining consciousness by most studies, except for one paper that used a 5‐minute limit.[6](#epi14515-bib-0006){ref-type="ref"} In 21 studies including adults, definitions were more variable, including 30‐minute seizure duration limits,[7](#epi14515-bib-0007){ref-type="ref"}, [8](#epi14515-bib-0008){ref-type="ref"}, [9](#epi14515-bib-0009){ref-type="ref"}, [10](#epi14515-bib-0010){ref-type="ref"}, [11](#epi14515-bib-0011){ref-type="ref"}, [12](#epi14515-bib-0012){ref-type="ref"}, [13](#epi14515-bib-0013){ref-type="ref"} and 5‐minute clinical seizure duration or more than two seizures without return to baseline between seizures.[14](#epi14515-bib-0014){ref-type="ref"}, [15](#epi14515-bib-0015){ref-type="ref"}, [16](#epi14515-bib-0016){ref-type="ref"}, [17](#epi14515-bib-0017){ref-type="ref"}, [18](#epi14515-bib-0018){ref-type="ref"}, [19](#epi14515-bib-0019){ref-type="ref"} One study also chose a 10‐minute clinical seizure duration cutoff limit.[20](#epi14515-bib-0020){ref-type="ref"} Two studies reported patients with prolonged refractory SE, including patients with SE that persists or recurs over a period of ≥7 days after the initiation of continuous general anesthesia.[21](#epi14515-bib-0021){ref-type="ref"}, [22](#epi14515-bib-0022){ref-type="ref"} Super‐refractory SE (SRSE) was defined as SE that continues or recurs ≥24 hours after the onset of anesthesic therapy, including those cases that recur on the reduction or withdrawal of anesthesia.[23](#epi14515-bib-0023){ref-type="ref"} Of note, the definition of RSE was also variable, but usually referred to SE that continues after administration of a benzodiazepine and a second antiseizure medication. One study defined RSE as SE lasting \>60 minutes.[24](#epi14515-bib-0024){ref-type="ref"}

4. APPROACH TO INTENSIVE CARE UNIT TREATMENT OF SE {#epi14515-sec-0005}
==================================================

Treatment of SE mostly follows general treatment guidelines and algorithms.[1](#epi14515-bib-0001){ref-type="ref"}, [2](#epi14515-bib-0002){ref-type="ref"} The first line usually consists of benzodiazepines, often followed by intravenous nonbenzodiazepine antiseizure medications (ASMs). If SE continues and becomes refractory, guidelines recommend transfer to the intensive care unit and additional anesthetic treatment, ideally within 30 or 40 minutes after SE onset.[1](#epi14515-bib-0001){ref-type="ref"}, [2](#epi14515-bib-0002){ref-type="ref"}, [25](#epi14515-bib-0025){ref-type="ref"} The most common drugs at this treatment stage are continuous infusions of midazolam, infusions of pentobarbital/thiopental, or intermittent phenobarbital doses.[1](#epi14515-bib-0001){ref-type="ref"} Main adverse events may include respiratory depression and hypotension, and thus mechanical ventilation and blood pressure management are often needed.[25](#epi14515-bib-0025){ref-type="ref"} Currently, class I evidence supports the use of benzodiazepines as first‐line treatments, and a major randomized controlled trial is in progress in an attempt to obtain data supporting choices of second‐line treatment (Established Status Epilepticus Treatment Trial). Limited data support third‐line treatment choices.[2](#epi14515-bib-0002){ref-type="ref"}

5. LONG‐TERM OUTCOMES OF SE {#epi14515-sec-0006}
===========================

5.1. Subsequent epilepsy {#epi14515-sec-0007}
------------------------

The risk of subsequent epilepsy after SE is high in both children and adults, with highest onset risk during the first year of follow‐up.[4](#epi14515-bib-0004){ref-type="ref"} In pediatric patients, this risk ranges from 5% to 36%.[6](#epi14515-bib-0006){ref-type="ref"}, [26](#epi14515-bib-0026){ref-type="ref"}, [27](#epi14515-bib-0027){ref-type="ref"}, [28](#epi14515-bib-0028){ref-type="ref"}, [29](#epi14515-bib-0029){ref-type="ref"} In mixed populations of adults and children, subsequent epilepsy after SE may occur in 22%‐41%,[14](#epi14515-bib-0014){ref-type="ref"}, [30](#epi14515-bib-0030){ref-type="ref"} which is less than in patients with history of RSE, who have a 87.5% risk of subsequent epilepsy.[14](#epi14515-bib-0014){ref-type="ref"} Only one adult study showed that 31% of patients have subsequent epilepsy or worsening of previous epilepsy after SE.[20](#epi14515-bib-0020){ref-type="ref"} The main predictor of subsequent epilepsy is the underlying SE etiology, and nonfebrile‐nonidiopathic,[28](#epi14515-bib-0028){ref-type="ref"} remote symptomatic,[29](#epi14515-bib-0029){ref-type="ref"} structural, and acute symptomatic (eg, anoxic brain injury)[30](#epi14515-bib-0030){ref-type="ref"} etiologies are usually associated with higher risk. In comparison, the risk of subsequent epilepsy after a single seizure is 40%‐50%.[31](#epi14515-bib-0031){ref-type="ref"}, [32](#epi14515-bib-0032){ref-type="ref"} In terms of epilepsy severity after SE, epilepsy becomes refractory in 15%‐25% of children after SE, which is not markedly different from the proportion of refractory cases in the general epileptic population.[6](#epi14515-bib-0006){ref-type="ref"}, [33](#epi14515-bib-0033){ref-type="ref"} In a population‐based series of 115 children with epilepsy, those who had SE, when compared with those who did not have an SE event, had a lower probability of epilepsy remission (55% vs 80%; risk ratio = 0.58, 95% confidence interval = 0.34‐0.99, *P *=* *0.044). The patient who had SE also had a lower probability of epilepsy remission off ASMs (39% vs 65%; risk ratio = 0.50, 95% confidence interval = 0.27‐0.95, *P *=* *0.029),[34](#epi14515-bib-0034){ref-type="ref"} suggesting a more refractory epilepsy in these patients.[33](#epi14515-bib-0033){ref-type="ref"}, [34](#epi14515-bib-0034){ref-type="ref"} In contrast, a study of 188 children with focal epilepsy found no statistically significant difference in the probability of epilepsy remission off ASM in patients who have SE events (61% in patients with SE vs 66% in patients without SE, *P *=* *0.5).[5](#epi14515-bib-0005){ref-type="ref"}

5.2. Recurrence of SE {#epi14515-sec-0008}
---------------------

In patients with SE, the occurrence of recurrent SE ranges from 10% to 56% in children[28](#epi14515-bib-0028){ref-type="ref"}, [29](#epi14515-bib-0029){ref-type="ref"}, [34](#epi14515-bib-0034){ref-type="ref"}, [35](#epi14515-bib-0035){ref-type="ref"} and from 13% to 37% in mixed population of adults and children.[8](#epi14515-bib-0008){ref-type="ref"}, [9](#epi14515-bib-0009){ref-type="ref"} Predictors of recurrent SE include age \< 4 years,[8](#epi14515-bib-0008){ref-type="ref"} female gender, nonresponse to first ASM for SE,[9](#epi14515-bib-0009){ref-type="ref"} and remote symptomatic and progressive etiologies.[9](#epi14515-bib-0009){ref-type="ref"}, [35](#epi14515-bib-0035){ref-type="ref"}

5.3. Cognitive outcome and functional outcome {#epi14515-sec-0009}
---------------------------------------------

Cognitive, functional, and QoL sequelae are frequent, especially in RSE and SRSE.[16](#epi14515-bib-0016){ref-type="ref"}, [20](#epi14515-bib-0020){ref-type="ref"} Long‐term cognitive sequelae occur in 28%‐34% of children.[28](#epi14515-bib-0028){ref-type="ref"}, [33](#epi14515-bib-0033){ref-type="ref"}, [36](#epi14515-bib-0036){ref-type="ref"}, [37](#epi14515-bib-0037){ref-type="ref"} In one adult study on long‐term cognitive sequelae after SE, no cognitive decline was found after 3 years of follow‐up, but this series included only 15 patients.[10](#epi14515-bib-0010){ref-type="ref"} Cognitive outcomes are usually evaluated based on clinical judgment or measured using a wide variety of neuropsychological tests. The underlying etiology is the main factor associated with long‐term cognitive outcome in children,[6](#epi14515-bib-0006){ref-type="ref"}, [28](#epi14515-bib-0028){ref-type="ref"}, [33](#epi14515-bib-0033){ref-type="ref"}, [36](#epi14515-bib-0036){ref-type="ref"}, [38](#epi14515-bib-0038){ref-type="ref"} with symptomatic SE[28](#epi14515-bib-0028){ref-type="ref"}, [36](#epi14515-bib-0036){ref-type="ref"}, [38](#epi14515-bib-0038){ref-type="ref"} or progressive encephalopathy[36](#epi14515-bib-0036){ref-type="ref"} contributing to increased risk. Other factors are young age at the time of SE[28](#epi14515-bib-0028){ref-type="ref"}, [36](#epi14515-bib-0036){ref-type="ref"}, [38](#epi14515-bib-0038){ref-type="ref"} and neuroimaging abnormalities[28](#epi14515-bib-0028){ref-type="ref"} (Table [1](#epi14515-tbl-0001){ref-type="table"}). Also, seizure burden in uncontrolled epilepsy, rather than SE, is more frequently associated with poor cognitive outcome.[39](#epi14515-bib-0039){ref-type="ref"}, [40](#epi14515-bib-0040){ref-type="ref"}

The impact of SE on cognitive outcome is debatable. Animal models show that prolonged seizures result in neuronal loss and brain connectivity changes.[41](#epi14515-bib-0041){ref-type="ref"}, [42](#epi14515-bib-0042){ref-type="ref"} A clinical study showed that children with SE had worse long‐term cognitive outcome than healthy controls, with nonfebrile SE associated with worse cognitive impairments than febrile SE.[37](#epi14515-bib-0037){ref-type="ref"} In contrast, large studies showed no difference in cognitive outcome when comparing children with and without SE, although controls in this study were children with epilepsy.[33](#epi14515-bib-0033){ref-type="ref"}, [34](#epi14515-bib-0034){ref-type="ref"} Most adult studies focus on functional rather than cognitive outcomes using standardized scales like the modified Rankin Score and the Glasgow Outcome Scale, with functional deficits seen in 21‐61%,[16](#epi14515-bib-0016){ref-type="ref"}, [20](#epi14515-bib-0020){ref-type="ref"}, [21](#epi14515-bib-0021){ref-type="ref"}, [43](#epi14515-bib-0043){ref-type="ref"}, [44](#epi14515-bib-0044){ref-type="ref"} and these could be more severe in RSE[20](#epi14515-bib-0020){ref-type="ref"} or SRSE (67%).[16](#epi14515-bib-0016){ref-type="ref"} Functional outcomes in children are mostly based on clinical impression, yielding a wide spectrum of functional impairment after SE from 0% to 79%,[6](#epi14515-bib-0006){ref-type="ref"}, [17](#epi14515-bib-0017){ref-type="ref"}, [24](#epi14515-bib-0024){ref-type="ref"}, [26](#epi14515-bib-0026){ref-type="ref"}, [27](#epi14515-bib-0027){ref-type="ref"}, [28](#epi14515-bib-0028){ref-type="ref"}, [29](#epi14515-bib-0029){ref-type="ref"}, [35](#epi14515-bib-0035){ref-type="ref"}, [36](#epi14515-bib-0036){ref-type="ref"}, [38](#epi14515-bib-0038){ref-type="ref"}, [45](#epi14515-bib-0045){ref-type="ref"} and this range may also be related to different definitions and assessment of impairment, and often lack of good baseline information. The evaluation of long‐term cognitive outcomes is further complicated by evolution over time in some cases, and in particular outcomes in children are often not static as development progresses. In a pediatric study, impaired performance at discharge persisted at 1 year,[37](#epi14515-bib-0037){ref-type="ref"} whereas in another series deficits disappeared or improved over time.[15](#epi14515-bib-0015){ref-type="ref"}, [22](#epi14515-bib-0022){ref-type="ref"}, [46](#epi14515-bib-0046){ref-type="ref"} Predictors of poor functional outcome include etiology (nonfebrile SE, acute symptomatic SE, progressive encephalopathy)[17](#epi14515-bib-0017){ref-type="ref"}, [26](#epi14515-bib-0026){ref-type="ref"}, [28](#epi14515-bib-0028){ref-type="ref"}, [36](#epi14515-bib-0036){ref-type="ref"}, [37](#epi14515-bib-0037){ref-type="ref"} and SE duration[17](#epi14515-bib-0017){ref-type="ref"}, [26](#epi14515-bib-0026){ref-type="ref"}, [27](#epi14515-bib-0027){ref-type="ref"}, [45](#epi14515-bib-0045){ref-type="ref"} (Table [1](#epi14515-tbl-0001){ref-type="table"}).

5.4. QoL {#epi14515-sec-0010}
--------

There is limited literature on QoL after SE. Compared to short seizures, convulsive or electrographic‐only SE[45](#epi14515-bib-0045){ref-type="ref"} has a negative impact on the long‐term QoL.[5](#epi14515-bib-0005){ref-type="ref"} However, population‐based studies comparing adults with childhood‐onset epilepsy with or without SE showed no association with educational attainment, employment status, and income.[33](#epi14515-bib-0033){ref-type="ref"} Patients after RSE may achieve an equivalent QoL as compared to patients after non‐RSE.[18](#epi14515-bib-0018){ref-type="ref"} However, patients in seizure remission present better QoL results as compared to patients with SE.[18](#epi14515-bib-0018){ref-type="ref"} Other prospective studies showed only small associations between SE and selected domains of QoL.[34](#epi14515-bib-0034){ref-type="ref"}, [47](#epi14515-bib-0047){ref-type="ref"}

5.5. Mortality {#epi14515-sec-0011}
--------------

Short‐term mortality of SE ranges from 0% to 4%[26](#epi14515-bib-0026){ref-type="ref"}, [48](#epi14515-bib-0048){ref-type="ref"}, [49](#epi14515-bib-0049){ref-type="ref"} in children and 2%‐40% in adults, with higher mortality in RSE.[26](#epi14515-bib-0026){ref-type="ref"}, [48](#epi14515-bib-0048){ref-type="ref"}, [50](#epi14515-bib-0050){ref-type="ref"}, [51](#epi14515-bib-0051){ref-type="ref"}, [52](#epi14515-bib-0052){ref-type="ref"} Long‐term mortality data after an episode of SE, including in‐hospital deaths, is 0%‐22% in children[5](#epi14515-bib-0005){ref-type="ref"}, [6](#epi14515-bib-0006){ref-type="ref"}, [17](#epi14515-bib-0017){ref-type="ref"}, [26](#epi14515-bib-0026){ref-type="ref"}, [27](#epi14515-bib-0027){ref-type="ref"}, [28](#epi14515-bib-0028){ref-type="ref"}, [29](#epi14515-bib-0029){ref-type="ref"}, [33](#epi14515-bib-0033){ref-type="ref"}, [34](#epi14515-bib-0034){ref-type="ref"}, [35](#epi14515-bib-0035){ref-type="ref"}, [37](#epi14515-bib-0037){ref-type="ref"}, [38](#epi14515-bib-0038){ref-type="ref"}, [45](#epi14515-bib-0045){ref-type="ref"}, [53](#epi14515-bib-0053){ref-type="ref"} and 0%‐57% in adults.[10](#epi14515-bib-0010){ref-type="ref"}, [11](#epi14515-bib-0011){ref-type="ref"}, [12](#epi14515-bib-0012){ref-type="ref"}, [17](#epi14515-bib-0017){ref-type="ref"}, [19](#epi14515-bib-0019){ref-type="ref"}, [20](#epi14515-bib-0020){ref-type="ref"}, [43](#epi14515-bib-0043){ref-type="ref"}, [54](#epi14515-bib-0054){ref-type="ref"} Although long‐term mortality rates are high, the underlying etiology and the period of follow‐up are major determinants of outcome. A population‐based study reported 24 deaths among 150 patients with childhood onset epilepsy, but mortality was similar in those with or without prior SE.[34](#epi14515-bib-0034){ref-type="ref"} A prospective study including 206 children identified preexisting neurological comorbidities as a predictor of mortality.[53](#epi14515-bib-0053){ref-type="ref"} Risk factors for mortality in adults include etiology (progressive, remote, or acute symptomatic causes),[8](#epi14515-bib-0008){ref-type="ref"}, [12](#epi14515-bib-0012){ref-type="ref"}, [13](#epi14515-bib-0013){ref-type="ref"}, [24](#epi14515-bib-0024){ref-type="ref"}, [55](#epi14515-bib-0055){ref-type="ref"} older age,[11](#epi14515-bib-0011){ref-type="ref"}, [12](#epi14515-bib-0012){ref-type="ref"} SE duration,[8](#epi14515-bib-0008){ref-type="ref"}, [13](#epi14515-bib-0013){ref-type="ref"}, [56](#epi14515-bib-0056){ref-type="ref"} and development of subsequent epilepsy.[11](#epi14515-bib-0011){ref-type="ref"} The Status Epilepticus Severity Score is a valuable tool to assess in‐hospital mortality but has not been clearly validated to estimate long‐term mortality.[57](#epi14515-bib-0057){ref-type="ref"}, [58](#epi14515-bib-0058){ref-type="ref"}, [59](#epi14515-bib-0059){ref-type="ref"} The Epidemiology‐Based Mortality in Status Epilepticus score considers etiology, age, electroencephalogram, and comorbidities and has been associated with poor long‐term outcome in one prospective study.[19](#epi14515-bib-0019){ref-type="ref"}

5.6. Health care utilization and cost {#epi14515-sec-0012}
-------------------------------------

There are limited data on short‐term resource utilization in SE. Studies on mean SE cost estimated up to US\$18 834 in the USA and up to €14 946 in Germany per admission, significantly higher than those related to admissions of patients with epilepsy (€1998‐€3475).[56](#epi14515-bib-0056){ref-type="ref"}, [60](#epi14515-bib-0060){ref-type="ref"}, [61](#epi14515-bib-0061){ref-type="ref"} However, these studies reflect the in‐hospital treatment, but SE is also associated with indirect costs because of unfavorable outcomes and costs or tentative income loss for those caring for patients with epilepsy.[62](#epi14515-bib-0062){ref-type="ref"} Surprisingly, there is a lack of studies on long‐term resource utilization due to SE.

6. DIFFERENCES BETWEEN ADULT AND PEDIATRIC POPULATION {#epi14515-sec-0013}
=====================================================

Age is one of the main outcome predictors after SE,[53](#epi14515-bib-0053){ref-type="ref"} with the youngest (\<1 year)[13](#epi14515-bib-0013){ref-type="ref"}, [28](#epi14515-bib-0028){ref-type="ref"}, [36](#epi14515-bib-0036){ref-type="ref"}, [38](#epi14515-bib-0038){ref-type="ref"} and oldest[11](#epi14515-bib-0011){ref-type="ref"}, [12](#epi14515-bib-0012){ref-type="ref"}, [20](#epi14515-bib-0020){ref-type="ref"} patients having the poorest long‐term outcomes (\>65 years[11](#epi14515-bib-0011){ref-type="ref"} or odds/risk ratio = 1.04‐1.05/year[12](#epi14515-bib-0012){ref-type="ref"}, [20](#epi14515-bib-0020){ref-type="ref"}). The higher mortality reported in younger children may also reflect the higher proportion of acute symptomatic cases in this age group.[63](#epi14515-bib-0063){ref-type="ref"}, [64](#epi14515-bib-0064){ref-type="ref"}, [65](#epi14515-bib-0065){ref-type="ref"} Of note, animal models have shown that immature neurons are more resistant to neuronal damage after a prolonged seizure.[66](#epi14515-bib-0066){ref-type="ref"}, [67](#epi14515-bib-0067){ref-type="ref"} This may be reflected in the finding that children have fewer cognitive sequelae of SE and lower mortality than adults.[13](#epi14515-bib-0013){ref-type="ref"}, [68](#epi14515-bib-0068){ref-type="ref"} However, sequelae in children usually affect a longer expected lifespan than in adults and the elderly.[69](#epi14515-bib-0069){ref-type="ref"}

7. FACTORS AFFECTING OUTCOME {#epi14515-sec-0014}
============================

7.1. SE etiology {#epi14515-sec-0015}
----------------

As in short‐term studies, etiology is the main determinant of long‐term morbidity and mortality related to SE, probably more than the SE episode itself.[33](#epi14515-bib-0033){ref-type="ref"}, [34](#epi14515-bib-0034){ref-type="ref"}, [55](#epi14515-bib-0055){ref-type="ref"} A large majority of studies assigned the etiology of SE into broad categories (acute symptomatic, progressive symptomatic, remote symptomatic, and idiopathic/cryptogenic) based on previous work and International League Against Epilepsy recommendations,[70](#epi14515-bib-0070){ref-type="ref"} but the category assignments may in part contain information bias, and various classifications are used.

In adults, etiologies associated with poor outcome include hypoxia,[7](#epi14515-bib-0007){ref-type="ref"}, [8](#epi14515-bib-0008){ref-type="ref"}, [13](#epi14515-bib-0013){ref-type="ref"} acute symptomatic,[12](#epi14515-bib-0012){ref-type="ref"}, [20](#epi14515-bib-0020){ref-type="ref"}, [44](#epi14515-bib-0044){ref-type="ref"}, [45](#epi14515-bib-0045){ref-type="ref"}, [55](#epi14515-bib-0055){ref-type="ref"} and progressive symptomatic causes.[9](#epi14515-bib-0009){ref-type="ref"}, [12](#epi14515-bib-0012){ref-type="ref"} In children, many studies have pointed out remote[29](#epi14515-bib-0029){ref-type="ref"}, [35](#epi14515-bib-0035){ref-type="ref"}, [36](#epi14515-bib-0036){ref-type="ref"} and acute[6](#epi14515-bib-0006){ref-type="ref"}, [17](#epi14515-bib-0017){ref-type="ref"}, [24](#epi14515-bib-0024){ref-type="ref"}, [26](#epi14515-bib-0026){ref-type="ref"}, [71](#epi14515-bib-0071){ref-type="ref"} symptomatic causes, progressive encephalopathies,[17](#epi14515-bib-0017){ref-type="ref"}, [26](#epi14515-bib-0026){ref-type="ref"}, [35](#epi14515-bib-0035){ref-type="ref"}, [36](#epi14515-bib-0036){ref-type="ref"} or more extensively "nonfebrile‐nonidiopathic SE"[28](#epi14515-bib-0028){ref-type="ref"} as predictors of poor outcome. In contrast, the risks of mortality[53](#epi14515-bib-0053){ref-type="ref"} and neurological deficits are low with febrile SE and cryptogenic/idiopathic SE.[26](#epi14515-bib-0026){ref-type="ref"}, [27](#epi14515-bib-0027){ref-type="ref"}, [28](#epi14515-bib-0028){ref-type="ref"}, [72](#epi14515-bib-0072){ref-type="ref"} However, the specific subcategory of presumed encephalitis or new onset refractory SE may be associated with worse long‐term outcome[16](#epi14515-bib-0016){ref-type="ref"}, [73](#epi14515-bib-0073){ref-type="ref"}, [74](#epi14515-bib-0074){ref-type="ref"} and prolonged duration of SE.[21](#epi14515-bib-0021){ref-type="ref"}

7.2. Treatment {#epi14515-sec-0016}
--------------

There is not sufficient evidence for the efficacy of treatment of RSE with anesthetic medications.[2](#epi14515-bib-0002){ref-type="ref"}

Notably, some studies suggest that the use of intravenous anesthetic drugs (IVADs) is associated with negative outcomes.[75](#epi14515-bib-0075){ref-type="ref"}, [76](#epi14515-bib-0076){ref-type="ref"} Especially pentobarbital has been linked to the development of hypotension requiring prolonged duration of mechanical ventilation and vasopressor therapies,[76](#epi14515-bib-0076){ref-type="ref"} which have in turn been associated with poor long‐term outcome.[54](#epi14515-bib-0054){ref-type="ref"} Continuous infusion of thiopental was also associated with more frequent adverse events and worse outcome at 6 months compared to continuous infusions of midazolam.[77](#epi14515-bib-0077){ref-type="ref"} However, it is discussed whether the association with negative outcomes is effectively due to the use of IVADs, or due to confounding by indication, as patients who require continuous infusions are probably more critically ill.[78](#epi14515-bib-0078){ref-type="ref"} A recent prospective two‐site cohort study matched 406 patients (139 with IVADs) and found worse outcome in the group receiving IVADs, after adjusting for known outcome predictors.[79](#epi14515-bib-0079){ref-type="ref"} In a review of long‐term mortality in relationship to IVADs, the death rate was higher with thiopental/pentobarbital (46%) compared with propofol (36%), midazolam (34%), and ketamine (44%).[80](#epi14515-bib-0080){ref-type="ref"} However, there may be unknown predictors affecting outcome, and therefore additional comparative effectiveness data and randomized controlled trials are needed in this area.

Patients with SRSE are more likely to require multiple medication combinations and prolonged hospitalizations and to present severe deconditioning and often systemic complications. Systemic complications of SE can determine long‐term morbidity and mortality, including cardiomyopathy, pulmonary edema, and renal failure.[11](#epi14515-bib-0011){ref-type="ref"}, [81](#epi14515-bib-0081){ref-type="ref"} It remains unclear how medical treatments affect long‐term outcome of SE.

7.3. Short‐ and long‐term effect of acute treatment of SE {#epi14515-sec-0017}
---------------------------------------------------------

Most literature on the treatment of SE considers short‐term endpoints like seizure control or in‐hospital mortality. Delays in time to treatment are independently associated with worse outcomes in the short term (higher mortality, higher need for continuous infusions, longer convulsive duration, and more frequent hypotension).[1](#epi14515-bib-0001){ref-type="ref"}, [2](#epi14515-bib-0002){ref-type="ref"}, [3](#epi14515-bib-0003){ref-type="ref"}, [33](#epi14515-bib-0033){ref-type="ref"}, [82](#epi14515-bib-0082){ref-type="ref"}, [83](#epi14515-bib-0083){ref-type="ref"} Families and caregivers play a crucial role, as timely treatment is often possible if families and caregivers administer a rescue medication at home and quickly call emergency services.[84](#epi14515-bib-0084){ref-type="ref"}, [85](#epi14515-bib-0085){ref-type="ref"}, [86](#epi14515-bib-0086){ref-type="ref"} However, a survey of 100 families of patients with epilepsy showed that 87% had a rescue medication prescription, but only 61% of them reported receiving training on how to use it.[86](#epi14515-bib-0086){ref-type="ref"}, [87](#epi14515-bib-0087){ref-type="ref"} Furthermore, a study showed that only 37.5% of patients received prehospital treatment.[85](#epi14515-bib-0085){ref-type="ref"} Improving these factors could impact short‐term outcomes. However, the influence of acute treatment of SE on long‐term outcomes appears unclear, and the main predictor of long‐term outcome appears to be SE etiology.[53](#epi14515-bib-0053){ref-type="ref"}

8. LIMITATIONS {#epi14515-sec-0018}
==============

Current data need to be interpreted in the setting of often retrospective or unstructured outcome assessment. Additionally, study populations are heterogeneous, different definitions of SE are often applied, and data are acquired in different geographical, socioeconomic, and health care system settings. In addition, follow‐up duration and the outcome measures are often variable, reflecting lack of standardized data collection or related guidelines in this field. The current literature does not permit a comparison between results from SE and RSE studies, as they differ in many aspects, including heterogeneity of study populations and study design. Thus far, SE patients are by and large not systematically followed with validated tests repeated over time, or through standardized clinical outcome tools over time. Lastly, we also acknowledge publication bias of specific results, and many publications may suffer from selection and information biases.[80](#epi14515-bib-0080){ref-type="ref"}

9. OUTLOOK {#epi14515-sec-0019}
==========

Long‐term outcome after SE encompasses multiple domains including development of subsequent epilepsy, functional and cognitive deficits, and QoL. Mortality remains high, exacerbated by underlying neurological comorbidities, and about one‐third of the children develop cognitive sequelae after RSE. Etiology is the main determinant of long‐term outcome, but age, treatment timing, and status duration may also play a role, with potential opportunity for care improvements in the latter two. Future studies may either include larger numbers to adjust for confounders or focus on specific etiologies. There is an urgent need for large prospective and multicenter studies, adjusted for confounders and stratified by seizure type, etiology, treatment timing, and age to account for SE heterogeneity, using validated outcome measures, responsive to the intervention. For example, safety studies comparing midazolam, propofol, and barbiturates could be considered, also taking into the account the impact of adverse events caused by prolonged deep sedation[88](#epi14515-bib-0088){ref-type="ref"} and considering electroencephalographic endpoint and duration of anesthetic treatments, such as seizure suppression or burst suppression, and related long‐term outcomes. Neuroprotective approaches are likely to improve outcome of patients with acute symptomatic causes, which seems to be one of the most important risk factors.[20](#epi14515-bib-0020){ref-type="ref"} Some studies have demonstrated that functional outcome and likely QoL may improve over time.[15](#epi14515-bib-0015){ref-type="ref"}, [18](#epi14515-bib-0018){ref-type="ref"}, [22](#epi14515-bib-0022){ref-type="ref"}, [23](#epi14515-bib-0023){ref-type="ref"} Promising research in animal models is in the process of identifying biomarkers that can be modulated to minimize long‐term functional impairment.[89](#epi14515-bib-0089){ref-type="ref"}, [90](#epi14515-bib-0090){ref-type="ref"} Additional comparative effectiveness and interventional trials are underway to provide additional data. Translational and clinical research may move these findings to clinical practice in the near future.
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